Short Interest in Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) Declines By 16.7%

Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) saw a significant decrease in short interest during the month of March. As of March 31st, there was short interest totaling 360,085 shares, a decrease of 16.7% from the March 15th total of 432,240 shares. Based on an average daily volume of 273,695 shares, the days-to-cover ratio is currently 1.3 days.

Inspira Technologies OXY B.H.N. Stock Up 0.6%

NASDAQ:IINN traded up $0.00 during trading hours on Friday, reaching $0.50. 295,157 shares of the company were exchanged, compared to its average volume of 377,651. Inspira Technologies OXY B.H.N. has a 1-year low of $0.34 and a 1-year high of $1.65. The company has a current ratio of 1.56, a quick ratio of 1.30 and a debt-to-equity ratio of 0.08. The business has a 50 day moving average of $0.54 and a 200 day moving average of $0.83.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Inspira Technologies OXY B.H.N. in a research report on Friday, April 10th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $2.00.

Institutional Investors Weigh In On Inspira Technologies OXY B.H.N.

Large investors have recently added to or reduced their stakes in the stock. Kestra Advisory Services LLC acquired a new stake in Inspira Technologies OXY B.H.N. during the fourth quarter worth approximately $71,000. Citadel Advisors LLC bought a new stake in Inspira Technologies OXY B.H.N. during the third quarter worth $105,000. Finally, Yorkville Advisors Global LP bought a new stake in Inspira Technologies OXY B.H.N. during the fourth quarter worth $1,605,000. Institutional investors and hedge funds own 12.72% of the company’s stock.

About Inspira Technologies OXY B.H.N.

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels.